Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer

Not Applicable

• Conditions: Radiation Exposure; Ovarian Insufficiency
• Interventions: Radiation: radioactive iodine

• Registration Number: NCT04396158
• Lead Sponsor: Assiut University

Brief Summary

Thyroid carcinoma is the most common endocrine malignancy. Surgery is the standard therapeutic approach for patients with differentiated thyroid carcinoma (DTC), followed by radioiodine (RAI) therapy if indicated. For women with DTC, the effects of RAI therapy on gonadal and reproductive function are an important consideration. This study aimed to evaluate the effects of RAI therapy on ovarian function.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-05
• Study First Submitted: 2020-05-16
• Study First Submitted QC: 2020-05-16
• Study First Posted: 2020-05-20
• Last Update Submitted: 2020-05-22
• Last Update Posted: 2020-05-27
• Study Start: 2020-06-15
• Primary Completion: 2021-06-15
• Study Completion: 2021-12-15

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 38

Inclusion Criteria

• Female patient in childbearing period.
• Female patient with differentiated thyroid carcinoma.
• Underwent thyroidectomy.
• Candidate for radioactive iodine therapy.

Exclusion Criteria

• • Male patients.

  • Postmenopausal female patients.
  • Female patients with undifferentiated thyroid carcinoma.
  • Pregnant female patients.
  • Lactating female patients.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
intervention	radioactive iodine	-

Primary Outcome Measures

Name	Time	Method
Level of anti-Müllerian (AMH) hormone	6 months	Level of anti-Müllerian (AMH) hormone in female patients before and after radioactive iodine therapy.